Clinical trials: Depression, Bipolar
Bipolar Depression
Proof Of Mechanism Study To Determine Efficacy Of PF-04455242 In Blocking Spiradoline (PF-00345768) Stimulated Prolactin Release
This study will be a Proof of Mechanism (POM) study to establish evidence of central pharmacodynamic activity for PF 04455242, and will be a parallel group, randomized, double blind, sponsor open study conducted in healthy male…
- Trial name
- NCT00988949
- Testing
- PF-04455242, spiradoline
- Where
- Singapore
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Bipolar Disorder
Decision-Making in Bipolar Disorder
Forty subjects with bipolar disorder who are not receiving a mood-stabilizing medication for the treatment of their illness will participate in this study.
- Trial name
- NCT01463111
- Testing
- Lithium, Valproate, Lamotrigine
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Emory University
Bipolar Disorder, Bipolar Depression
Efficacy of Convulsive Therapies for Bipolar Depression
This trial aims to assess the efficacy and tolerability of Magnetic Seizure Therapy (MST) as an alternative to electroconvulsive therapy (ECT) for Bipolar Disorder (BD).
- Conditions
- Bipolar Disorder, Bipolar Depression, Bipolar I Disorder, Bipolar II Disorder
- Trial name
- CORRECT-BD (NCT03641300)
- Testing
- Magnetic Seizure Therapy (MST), Electroconvulsive Therapy (ECT)
- Where
- 3 sites in Canada
- Volunteers
- 76 people
- Sponsor
- Centre for Addiction and Mental Health
Unipolar Depression, Bipolar Depression
Mechanism of Action of Electroconvulsive Therapy
This is an observational neuroimaging study assessing the effects of ECT on the brains of patients with unipolar and bipolar depression.
- Trial name
- MoA-ECT (NCT04059952)
- Testing
- Electroconvulsive Therapy
- Where
- United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Major Depressive Episode (MDE), Unipolar Disorder
Evaluating the Therapeutic Potential of Focal Electrically Administered Seizure Therapy (FEAST) in the Treatment of Depression: A Multicenter Randomized Clinical Trial
A significant proportion of patients remain resistant to antidepressant therapies, even when treatment is well managed. Electroconvulsive therapy (ECT) is a well-established method for treating certain severe and resistant…
- Conditions
- Major Depressive Episode (MDE), Unipolar Disorder, Bipolar 1 Disorder
- Trial name
- FEAST-AFT (NCT07857122)
- Testing
- Stimulation by the Sigma ECT/FEAST device, Stimulation by Sigmastim ECT 200J device administered in right unilateral (RUL), Stimulation by Sigmastim ECT 200J device administered in bilateral (BT)
- Where
- 5 sites in France, Monaco
- Volunteers
- 108 people
- Sponsor
- Centre Hospitalier St Anne
Major Depressive Disorder, Bipolar Disorder
Chart Review of Patients Undergoing Ketamine Infusions
The Canadian Rapid Treatment Center of Excellence (CRTCE) is a healthcare facility principally focused on providing best practices of intravenous ketamine treatment to adult patients suffering from mental health conditions.
- Conditions
- Major Depressive Disorder, Bipolar Disorder, Obsessive-Compulsive Disorder, Post Traumatic Stress Disorder
- Trial name
- NCT04209296
- Testing
- Ketamine Hydrochloride
- Where
- Canada
- Volunteers
- 891 people
- Sponsor
- Brain and Cognition Discovery Foundation
Bipolar Disorder
Does Risperidone Consta Reduce Relapse and Rehospitalization in Bipolar Disorder?
This study will evaluate the relative effectiveness of risperidone Consta injections occurring every 2 weeks in contrast to treatment as usual in preventing symptomatic relapse and rates of rehospitalization or admission into…
- Trial name
- Consta (NCT00571688)
- Testing
- Risperdal (risperidone) Consta, Treatment as usual
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Vanderbilt University
Bipolar Disorder (BD), Suicidality
Neural Correlates of Ketamine's Anti-suicidal Effects in Bipolar Depression
Bipolar disorder is characterized by manic episodes and episodes of extreme depressive feelings, also known as bipolar depression (BD).
- Trial name
- DEEPP (NCT05177146)
- Testing
- Intravenous Ketamine (IV)
- Where
- Canada
- Volunteers
- 16 people
- Sponsor
- Centre for Addiction and Mental Health
Mental Health Symptoms, Wearables
My Experiences: Leveraging Digital Technologies to Better Understand Mental Health
Mental health disorders are one of the most challenging chronic conditions to identify, treat and manage. This is largely due to the fact that diagnoses are almost entirely based on the patient's recall of current and past…
- Trial name
- NCT05753605
- Where
- United States
- Volunteers
- 302 people
- Sponsor
- 4YouandMe
Depression, Bipolar Disorders
Enhancing Outcomes, Reducing Costs: Evaluating Peer Support for Mood Disorders
The purpose of this study to evaluate peer-led mutual help organizations (MHOs) that target individuals with psychiatric diagnoses such as mood disorders, and provide evidence either supporting the expansion of such groups and…
- Conditions
- Depression, Bipolar Disorders, Mood Disorders
- Trial name
- NCT02242669
- Where
- 2 sites in United States
- Volunteers
- 371 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Depression, Anxiety
The CARE (Collaborative Adolescent Running Experience) Project
This study is being completed to see if participants activity levels may have an impact as a treatment for depression, or depressive symptoms.
- Conditions
- Depression, Anxiety, Major Depressive Disorder, Bipolar Disorder
- Trial name
- CARE (NCT05837351)
- Testing
- Exercise -Running
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Michigan
Major Depressive Disorder
Lithium Versus Paroxetine in Patients With Major Depression Who Have a Family History of Bipolar Disorder or Suicide
This study is being done to look at how well people respond to two very different drug treatments for depression. Clinically, people with depression can respond differently to drug treatments for reasons which are not always…
- Trial name
- NCT00400088
- Testing
- paroxetine, lithium
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- Nova Scotia Health Authority
Schizophrenia Disorders, Bipolar Disorders
MonPsy&Moi: A Digital Platform for Collecting Patient-Reported Experience and Outcome Measures in Psychiatry
Mental health disorders, with a 30% annual prevalence rate, are a leading cause of disability and reduced life expectancy. Despite their impact, patient-reported experience measures (PREMs) and outcome measures (PROMs) are…
- Conditions
- Schizophrenia Disorders, Bipolar Disorders, Major Depression
- Trial name
- Mon Psy & Moi (NCT06818227)
- Where
- France
- Volunteers
- 23,660 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Mood Disorder, Mania
Assessment of Cardiac Autonomic Behavior in Patients With Mood Disorders
The purpose of this study is to characterize the behavior of cardiac patients with Mood Disorders and its clinical course, interpreting the results from a theoretical framework of Chaos Theory and Complexity Theory and Systems as…
- Conditions
- Mood Disorder, Mania, Depression
- Trial name
- NCT01272518
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Sao Jose do Rio Preto Medical School
Bipolar Disorder (BD), Major Depressive Episode (MDE)
Validation of a Composite Medical Device Using a Blood Biomarker-based Algorithm and MDQ for the Diagnosis of Bipolar Disorder
The goal of this interventional clinical trial is to assess the diagnostic performance of a composite diagnostic medical devise based on blood-based in vitro diagnostic device and Mood Disorder Questionnaire (MDQ) in identifying…
- Conditions
- Bipolar Disorder (BD), Major Depressive Episode (MDE), Primary Care, Major Depression
- Trial name
- BIPOVITE (NCT07031817)
- Testing
- Venous blood sample for measuring blood biomarkers related to bipolar disorder, Standardized psychiatric assessment tools
- Where
- France
- Volunteers
- 623 people
- Sponsor
- University Hospital, Montpellier
Major Depressive Disorder, Suicidal Behavior
Basal Plasma Lithium Levels and Suicidal Events
Suicidal behavior is a major public health issue and there are currently no specific treatments for it. However, lithium, the reference treatment for bipolar disorder, have been shown to be effective in preventing suicidal risk.
- Conditions
- Major Depressive Disorder, Suicidal Behavior, Bipolar Disorder
- Trial name
- LIPS (NCT05409794)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 158 people
- Sponsor
- University Hospital, Montpellier
Anxiety, Depression
Ginger.io Behavioral Health Study
This Study will evaluate the impact of a smartphone-based platform on a range of outcomes for medically-underserved patients with mood disorders (e.g.
- Conditions
- Anxiety, Depression, Bipolar I Disorder, Bipolar II Disorder
- Trial name
- NCT02491307
- Testing
- Ginger.io Smartphone Application
- Where
- 4 sites in United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Community Health Center, Inc.
Psychosis, Substance Use Disorders
Clozapine Versus Olanzapine as Treatment for Comorbid Psychotic Disorder and Substance Use Disorder
The purpose of this trial is to determine if patients with comorbid psychotic disorder and substance use disorder will continue in treatment longer if treated with clozapine than with olanzapine, and will have greater reductions…
- Trial name
- NCT03857581
- Testing
- Clozapine, Olanzapine
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Augusta University
Bipolar Disorder, Depression
Brain Imaging to Understand the Role of Inflammation in N-Acetyl Cysteine (NAC) Treatment of Bipolar Depression
We are trying to understand what causes bipolar disorder and how medications treat bipolar depression. Particularly, we are looking at the importance of inflammation in the process.
- Trial name
- NCT03730064
- Testing
- N-acetyl cysteine (NAC)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Martin Lan
Bipolar Disorder, Bipolar Depression
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
X-CEED is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of azetukalner in adult participants diagnosed with bipolar I or II disorder who are currently in a…
- Conditions
- Bipolar Disorder, Bipolar Depression, Bipolar I Disorder, Bipolar II Disorder
- Trial name
- X-CEED (NCT07172516)
- Testing
- Azetukalner
- Where
- 44 sites in United States, Bulgaria and 2 more
- Volunteers
- 400 people
- Sponsor
- Xenon Pharmaceuticals Inc.